Publikationen der ALS-Forschungsgruppe an der Charité
Elective termination of respiratory therapy in amyotrophic lateral sclerosis
Meyer T, Dullinger JS, Münch C, Keil JP, Hempel E, Rosseau S,
Thalidomide causes sinus bradycardia in ALS
Meyer T, Maier A, Borisow N, Dullinger JS, Splettstösser G, Ohlraun S,
Progressive muscle atrophy. A rarely diagnosed variant of amyotrophic lateral sclerosis
Meyer T, Münch C, van Landeghem FK, Borisow N, Dullinger J, Linke
Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD
Münch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Krause BJ,
Frequency of a tau genotype in amyotrophic lateral sclerosis
Münch C, Prechter F, Xu R, Linke P, Prudlo J, Kuzma M,
Early-onset ALS with long-term survival associated with spastin gene mutation
Meyer T, Schwan A, Dullinger JS, Brocke J, Hoffmann KT, Nolte CH,
Publikationen mit Beteiligung der ALS-Forschungsgruppe an der Charité
Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis
Ludolph AC, Dorst J, Dreyhaupt J,
Prognostic factors in ALS: a comparison between Germany and China
Dorst J, Chen L, Rosenbohm A,
GABA B receptor encephalitis in a patient diagnosed with amyotrophic lateral sclerosis
Schumacher H, Meyer T, Prüss H.
Comprehensive analysis of the mutation spectrum in 301 German ALS families
Müller K, Brenner D, Weydt P,
Therapeutic decision in ALS patients: cross-cultural differences and clinical implications
Andersen PM, Kuzma-Kozakiewicz M, Keller J,
The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy
Rosenbohm A, Hirsch S, Volk AE,
Hot-spot KIF5A mutations cause familial ALS
Brenner D, Yilmaz R, Müller K,
July 2017 ENCALS statement on edaravone
Al-Chalabi A, Andersen PM, Chandran S,
Genome-wide association analysis identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis
van Rheenen W, Shatunov A, Dekker
